The burden of this paper is the suggestion that the defence capacity of the
immune system is rather limited. It cannot stand in readiness to deal with
a practically endless diversity and abundance of microbes. In contrast to
conventional thinking the current model proposes: (1) The core idea that ce
lls of the immune system are basically and constantly interconnected with h
ost cells (e.g., through TCR-MHC interactions) and that foreign antigens (p
eptides) may tend to obstruct such interactions. Peptides presented during
a viral infection typically decrease complementarity between the structures
that are the products of the major histocompatibility complex (MHC) genes
(or other genes related to it) and T cells. The altered MHC profile exposes
infected cells to a polyclonal immune attack from other T cells such that
tissue destruction occurs in an allograft rejection-like fashion. This may
explain why a substantial portion of T cell numbers is activated when only
a small number of specific T cells is 'obstructed' from functioning by the
presence of non-self peptides. (2) Phagocytes 'see' targets even in a nonim
mune host because complement distribution associated with polyreactive natu
ral antibodies magnifies sensitization differences between pathogens and ho
st cells. (3) There is only a probability that hypermutation will successfu
lly change the genome in some B cell clones to produce high affinity antibo
dies that prevent the re-infection of the host by the same pathogen, but ca
nnot conquer primary infections. (4) The history of the development of the
immune responses suggests that during prolonged interaction between host an
d microbes in our natural habitat, carried on over many generations, the ad
aptive antibody population may facilitate the evolution of the natural anti
body repertoire. The model predicts that microbes, which are not a part of
the local environment, may invade the organism without significant resistan
ce. The model is discussed in various interactions for survival in the cont
ext of infection and tumorigenicity. Copyright (C) 2001 S. Karger AG, Basel
.